Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reproductive Health

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    853 result(s) found for: Reproductive Health. Displaying page 1 of 43.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004112-10 Sponsor Protocol Number: PROTECTA Start Date*: 2020-12-16
    Sponsor Name:Ghent University Hospital
    Full Title: Randomized controlled trial comparing micronized progesterone (Amelgen ®) 400 mg BID versus 400 mg TID for luteal support in artificial vitrified/warmed single blastocyst transfer cycles with low p...
    Medical condition: Patients who undergo artificial vitrified/warmed single blastocyst transfer cycles with low progesterone (defined as <10mcg/l) on day of embryo transfer.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002135-30 Sponsor Protocol Number: NCT04379973 Start Date*: 2021-04-28
    Sponsor Name:Antwerp University Hospital (UZA)
    Full Title: Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel group pragmatic trial in infertile women with at least one pate...
    Medical condition: Infertility defined as lack of conception despite 12 months of unprotected intercourse, or three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001736-35 Sponsor Protocol Number: 15-OBE2109-001 Start Date*: 2016-08-29
    Sponsor Name:ObsEva SA
    Full Title: A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.
    Medical condition: Treatment of Endometriosis-Associated Pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    20.0 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004492-12 Sponsor Protocol Number: SCY-078-306 Start Date*: 2019-06-05
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects with Acute Vulvovaginal Candid...
    Medical condition: Acute Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-000134-34 Sponsor Protocol Number: TEAM(B115UCS2019) Start Date*: 2021-05-24
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
    Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000328-85 Sponsor Protocol Number: FINNHT1 Start Date*: 2017-05-18
    Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology
    Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life
    Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10027311 Menopause flushing LLT
    20.0 10041244 - Social circumstances 10076936 Impaired quality of life PT
    20.1 10038604 - Reproductive system and breast disorders 10027301 Menopausal hot flushes LLT
    20.1 10022891 - Investigations 10060858 Cardiovascular function test PT
    20.0 10041244 - Social circumstances 10027308 Menopause PT
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 10041244 - Social circumstances 10051775 Postmenopause PT
    20.0 10047065 - Vascular disorders 10048554 Endothelial dysfunction PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003810-42 Sponsor Protocol Number: Version2.0;18/12/2013 Start Date*: 2016-06-24
    Sponsor Name:University of Edinburgh (ACCORD) [...]
    1. University of Edinburgh (ACCORD)
    2. NHS Lothian (ACCORD)
    Full Title: A pragmatic group sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (GOT-IT Trial)
    Medical condition: Retained placenta
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004868 10038757 Retained placenta LLT
    16.1 100000004865 10038350 Removal retained placenta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001824-32 Sponsor Protocol Number: 116174 Start Date*: 2015-03-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005117-72 Sponsor Protocol Number: AG120-C-005 Start Date*: 2017-04-24
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
    Medical condition: Nonresectable or Metastatic Cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002812-33 Sponsor Protocol Number: 204824 Start Date*: 2016-02-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function ...
    Medical condition: Delayed Graft Function in Adult Subjects After Renal Transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10074474 Transplantation complications HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003788-67 Sponsor Protocol Number: FS1306 Start Date*: 2014-01-29
    Sponsor Name:Watson Laboratories, Inc. - A subsidiary of Actavis, Inc.
    Full Title: A Randomised, Parallel Group, Assessor-Blind, Multicentre Study to Compare the Safety and Efficacy of Watson rhFSH with Follitropin Alfa (GONAL-f) in Stimulating Multiple Follicular Development in ...
    Medical condition: Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016375-30 Sponsor Protocol Number: MK-0462-086 Start Date*: 2010-02-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura
    Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004266-25 Sponsor Protocol Number: 16-OBE001-005 Start Date*: 2017-02-24
    Sponsor Name:ObsEva S.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day ...
    Medical condition: Embryo implantation in women undergoing IVF or ICSI with Day 3 or Day 5 fresh embryo transfer cycles, in the context of Assisted Reproductive Technology (ART).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10073184 Embryo transfer LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018421-19 Sponsor Protocol Number: PASS Start Date*: 2010-05-05
    Sponsor Name:AMC
    Full Title: Preventive Antibiotics in Stroke Study
    Medical condition: Stroke and stroke-associated infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042244 Stroke LLT
    12.1 10021789 Infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002600-40 Sponsor Protocol Number: SCY-078-304 Start Date*: 2020-01-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvova...
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001232-11 Sponsor Protocol Number: 200622 Start Date*: 2016-11-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophi...
    Medical condition: severe hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016374-32 Sponsor Protocol Number: MK-0462-082 Start Date*: 2010-02-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adole...
    Medical condition: Acute treatment of migraine, with or without aura, in children and adolescents, ages 6 to 17 years, who do not have a satisfactory response to prior treatment with nonsteroidal anti-inflammatory dr...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) BE (Completed) ES (Completed) EE (Completed) LV (Completed) SE (Completed) FR (Completed) DK (Completed) GB (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000375-25 Sponsor Protocol Number: BotA-KKDS2016 Start Date*: 2016-04-19
    Sponsor Name:Danderyds sjukhus AB
    Full Title: Double blind placebo-controlled RCT of the efficacy and safety of intramuscular injections of Botulinum Toxin A as a treatment for provoked vestibulodynia
    Medical condition: Provoked vestibulodynia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002367-26 Sponsor Protocol Number: CLI18001/Lita-003 Start Date*: 2019-03-27
    Sponsor Name:Litaphar Laboratorios
    Full Title: A randomized, double-blind, three-arm, parallel-group, multicentre superiority study assessing the efficacy and safety of mifepristone (2.5 mg and 5 mg) vs. placebo for the treatment of endometrios...
    Medical condition: endometriosis in reproductive-age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BG (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004429-34 Sponsor Protocol Number: 2017.lipiodol.flush Start Date*: 2018-02-15
    Sponsor Name:UZ Brussel
    Full Title: Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study.
    Medical condition: Female subfertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042392 Subfertility (female) LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA